National Securities Lowers Yield10 Bioscience (NASDAQ:YTEN) to Neutral

Share on StockTwits

Yield10 Bioscience (NASDAQ:YTEN) was downgraded by equities researchers at National Securities from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Monday, MarketBeat reports.

Several other equities analysts also recently issued reports on YTEN. Zacks Investment Research reissued a “hold” rating on shares of Yield10 Bioscience in a report on Saturday, October 19th. Maxim Group reissued a “buy” rating and set a $0.50 price target on shares of Yield10 Bioscience in a report on Friday, November 15th. Finally, Aegis reissued a “buy” rating and set a $2.00 price target on shares of Yield10 Bioscience in a report on Tuesday, August 13th.

Shares of YTEN stock opened at $0.12 on Monday. Yield10 Bioscience has a 12-month low of $0.12 and a 12-month high of $1.77. The company has a market capitalization of $1.89 million, a P/E ratio of -0.13 and a beta of 3.15. The firm has a 50-day moving average price of $0.47 and a 200 day moving average price of $0.76. The company has a quick ratio of 1.99, a current ratio of 1.99 and a debt-to-equity ratio of 1.93.

Yield10 Bioscience (NASDAQ:YTEN) last announced its quarterly earnings results on Tuesday, November 12th. The specialty chemicals company reported ($0.16) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.16). Yield10 Bioscience had a negative net margin of 995.38% and a negative return on equity of 168.01%. The firm had revenue of $0.22 million during the quarter. As a group, research analysts expect that Yield10 Bioscience will post -0.66 earnings per share for the current year.

An institutional investor recently raised its position in Yield10 Bioscience stock. Renaissance Technologies LLC raised its stake in Yield10 Bioscience Inc (NASDAQ:YTEN) by 9.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 478,176 shares of the specialty chemicals company’s stock after acquiring an additional 41,500 shares during the quarter. Renaissance Technologies LLC owned about 3.83% of Yield10 Bioscience worth $463,000 as of its most recent filing with the Securities and Exchange Commission. 7.70% of the stock is owned by institutional investors and hedge funds.

Yield10 Bioscience Company Profile

Yield10 Bioscience, Inc, an agricultural bioscience company, engages in developing disruptive technologies for enhancing crop yield in the United States and Canada. The company, through its Smart Carbon Grid for Crops and T3 platforms, is involved in improving fundamental crop yield through enhanced photosynthetic carbon capture, as well as increased carbon utilization efficiency to increase seed yield.

Recommended Story: Treasury Bonds

Receive News & Ratings for Yield10 Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yield10 Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Harrow Health  Stock Price Up 8.2%
Harrow Health Stock Price Up 8.2%
Berry Petroleum  Shares Up 7.3%
Berry Petroleum Shares Up 7.3%
Oil States International  Stock Price Up 6.4%
Oil States International Stock Price Up 6.4%
Avantor  Trading Up 5.8%
Avantor Trading Up 5.8%
La Jolla Pharmaceutical  Trading 19.6% Higher
La Jolla Pharmaceutical Trading 19.6% Higher
Edison Nation  Sees Large Volume Increase
Edison Nation Sees Large Volume Increase


© 2006-2019 Ticker Report